Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine

AIDS. 2004 Nov 5;18(16):2213-5. doi: 10.1097/00002030-200411050-00019.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active
  • Dideoxynucleosides / administration & dosage
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Lamivudine / administration & dosage
  • Male
  • Middle Aged
  • Prospective Studies
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Time Factors
  • Treatment Failure
  • Zidovudine / administration & dosage

Substances

  • Dideoxynucleosides
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine
  • abacavir